WONG'S INT'L (00099) released its interim results, with a profit attributable to shareholders of HKD 50.397 million, marking a year-on-year turnaround from loss to profit.
Wang's International (00099) announced its interim results for the six months ended June 30, 2026, reporting revenues of HKD 1.258 billion, a decrease of 3.38% year-on-year; profit attributable to shareholders was HKD 50.397 million, compared to a loss of HKD 158 million in the same period last year; earnings per share were HKD 0.11.
WONG'S INT'L (00099) announced its interim results for the six months ending June 30, 2026, with the group achieving revenue of HKD 1.258 billion, a decrease of 3.38% year-on-year; the profit attributable to the companys owners was HKD 50.397 million, compared to a loss of HKD 158 million in the same period last year; earnings per share were HKD 0.11.
The profit attributable to the owners of the company was HKD 50.4 million, while in the same period last year there was a loss of HKD 158.4 million. The reported results included the value of the group's investment properties and completed property inventory (net of deferred tax) which decreased by HKD 2 million, compared to a decrease of HKD 214.8 million in the same period last year.
Related Articles
MAN WAH HLDGS (01999): Ruimai Technology's net profit attributable to the parent in the first half of the year was 61.1548 million yuan, a year-on-year decrease of 37.78%.
AJISEN (CHINA) (00538) announced its interim results, with shareholders profit amounting to 16.967 million yuan, a decrease of 30.0% compared to the same period last year.
IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.
MAN WAH HLDGS (01999): Ruimai Technology's net profit attributable to the parent in the first half of the year was 61.1548 million yuan, a year-on-year decrease of 37.78%.
AJISEN (CHINA) (00538) announced its interim results, with shareholders profit amounting to 16.967 million yuan, a decrease of 30.0% compared to the same period last year.
IMMUNEONCO-B(01541): The first patient has been administered in the Phase II clinical trial of IMM2510 combined with IMM27M as first-line treatment for advanced HCC.
RECOMMEND
